Benzinga | Jun 24, 2021 06:11AM EDT

HC Wainwright & Co. Initiates Coverage On Kronos Bio with Buy Rating, Announces Price Target of $35

HC Wainwright & Co. analyst Robert Burns initiates coverage on Kronos Bio (NASDAQ:KRON) with a Buy rating and announces Price Target of $35.